Zenagamtide weekly injections for weight loss in Asian adults with overweight or obesity
Tests zenagamtide against placebo in Asian adults with overweight or obesity.
Plain-language title generated from the registry record
Registry title: AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight
Key facts
- Where
- Assam, Chennai, Delhi, Hubbali, Hyderabad, Indore, Jaipur, Kohlapur, Kolhāpur, Kozhikode, Mumbai, Nagpur, Nashik, Pune, Surat, Vadodara, and Vellore, IndiaSee the 21 sites
- Phase
- Phase 3
Where in India
- All India Institute of Medical Science (AIIMS), GuwahatiAssam, IndiaNo longer taking part
- Madras Diabetes Research FoundationChennai, IndiaNo longer taking part
- Maulana Azad Medical CollegeDelhi, IndiaNo longer taking part
- Karnataka Medical College and Research InstituteHubbali, IndiaNo longer taking part
- Diabetes Research Center, HyderabadHyderabad, IndiaNo longer taking part
- Osmania General HospitalHyderabad, IndiaNo longer taking part
- TOTALL Diabetes Hormone InstituteIndore, IndiaNo longer taking part
- SMS HospitalJaipur, IndiaNo longer taking part
- Shree Mahalaxmi DIATONE InstituteKohlapur, IndiaNo longer taking part
- Excel Endocrine CentreKolhāpur, IndiaNo longer taking part
- Government Medical College, KozhikodeKozhikode, IndiaNo longer taking part
- BSES MG hospitalMumbai, IndiaNo longer taking part
- All India Institute of Medical Sciences (AIIMS) - NagpurNagpur, IndiaNo longer taking part
- Shalini Tai Meghe Hospital and Research CenterNagpur, IndiaNo longer taking part
- Vijan Hospital & Research CentreNashik, IndiaNo longer taking part
- Chellaram Diabetes InstitutePune, IndiaNo longer taking part
- Grant Medical Foundation Ruby Hall ClinicPune, IndiaNo longer taking part
- Nirmal Hospital Pvt Ltd.Surat, IndiaNo longer taking part
- GMERS Medical college and hospitalVadodara, IndiaNo longer taking part
- SSG Hospital, BarodaVadodara, IndiaNo longer taking part
- Christian Medical College Hospital, VelloreVellore, IndiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07668401
- Record updated
- 24 August 2026
- Original description
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide (the treatment being tested) or placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.Read full original descriptionShow less
Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13)
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide (the treatment being tested) or placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Inclusion: Male or female (sex assigned at birth, inclusive of all gender identities); Age 18 years or above at the time of signing the informed consent.
Exclusion: Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening; History of type 1 or type 2 diabetes mellitus; Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening.